Physician profile
Anna J Roy
NPI 1780055392
$1,783.64
in general payments reported to CMS, 2019-2025
10 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $90.83 · 2024: $600 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $62.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.39 |
| Education | $62.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.54 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.54 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Madrigal Pharmaceuticals | $162.63 | 2025 | Rezdiffra |
| Qol Medical, LLC | $155.79 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $155.36 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $66.16 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $52.09 | 2024-2025 | Entyvio |
| Gilead Sciences, INC. | $29.49 | 2025 | |
| Ironwood Pharmaceuticals, INC | $19.85 | 2025 | |
| Novo Nordisk INC | $18.19 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.